TABLE 2.
Follow up characteristics of the patients 3 months after starting the study Data are means ± S.D. or n (%). “Control” refers to subjects who did not have any evidence of HFpEF or DM.
| Control | Empagliflozin | Metformin | Insulin | |
|---|---|---|---|---|
| N | 10 | 10 | 10 | 10 |
| BMI (kg/m2) | 25.4 ± 1.7 | 27.1 ± 1.1* | 27.3 ± 1.2* | 28.0 ± 1.3* |
| SBP (mmHg) | 117.9 ± 7.9 | 118.7 ± 6.8 | 118.6 ± 6.9 | 120.0 ± 7.1 |
| DBP (mmHg) | 76.2 ± 8.7 | 78.9 ± 6.4 | 79.0 ± 6.5 | 79.3 ± 6.8 |
| Heart rate (bpm) | 77.6 ± 10.3 | 87.0 ± 7.8* | 86.9 ± 8.1* | 87.2 ± 8.2* |
| EF (%) | 65.6 ± 7.4 | 56.2 ± 5.0* | 55.9 ± 5.2* | 55.1 ± 5.0* |
| Laboratory parameters | ||||
| Plasma glucose (mg/dl) | 100.2 ± 28.8 | 159.8 ± 37.8* | 162.9 ± 38.6* | 163.3 ± 38.8* |
| Cholesterol (mg/dl) | 201.5 ± 22.4 | 205.6 ± 20.0 | 205.5 ± 20.3 | 205.9 ± 19.9 |
| LDL-cholesterol (mg/dl) | 130.1 ± 16.5 | 131.8 ± 19.4 | 132.1 ± 19.3 | 132.3 ± 19.4 |
| HDL-cholesterol (mg/dl) | 36.1 ± 3.6 | 37.2 ± 3.2 | 36.8 ± 3.6 | 37.0 ± 3.3 |
| Creatinine (mg/dl) | 0.9 ± 0.3 | 1.0 ± 0.2 | 1.0 ± 0.2 | 1.0 ± 0.2 |
| BNP (pg/ml) | — | 439.7 ± 23.8 | 444.5 ± 24.1 | 444.8 ± 24.6 |
BMI, body mass index; BNP, brain natriuretic peptide; DBP, diastolic blood pressure; EF, ejection fraction; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SBP, systolic blood pressure.
*P < 0.05 versus control.